THE Government continues work to strengthen the country’s cancer care system through strategic partnerships with international entities.

On August 26 of this year, the Government signed a contract with global leader in diagnostic and pharmaceutical products, Roche, to market Herceptin Subcutaneous (SC), an agent commonly used in the treatment of early stage Human Epidermal Growth Factor Receptor (HER) 2 Positive breast cancer.

The product was launched last Wednesday at the Terra Nova All-Suite Hotel in Kingston, to be distributed by Roche Pharma (Jamaica and Cayman).

In his address, Health Minister Dr Fenton Ferguson said that Herceptin SC will be a valuable addition to the country’s cancer treatment system.

“This is an achievement that is set to revolutionise the landscape for the treatment of HER 2 Positive breast cancer,” he said.

Citing breast cancer as the fifth leading cause of death in Jamaican women, Dr Ferguson said that a crucial area for reducing deaths from this disease is early detection.

“Early detection, in order to improve breast cancer outcome and survival, remains the fundamental cornerstone in managing the disease. As we continue to push for early detection in order to improve breast cancer outcome and survival, we recognise that strong and fruitful partnerships like this one will help us achieve this goal,” he noted.

Herceptin is a cellular antibody that inhibits the protein that fuels tumour growth and should be used in conjunction with surgery and chemotherapy treatment.

In an interview with JIS News, country manager for Roche Pharma, Jamaica and Cayman, Stewart Dougan, said that the medication is now available to the public at several institutions islandwide.

The product is being distributed locally by Facey Commodity Company Limited and Cari-Med Limited.

Dougan warned that the product should only be administered by a licensed health care professional.

-JIS